Travis Steed
Stock Analyst at Barclays
(2.78)
# 1,853
Out of 4,876 analysts
85
Total ratings
44.12%
Success rate
6.89%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $169.97 | +53.56% | 8 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $253.58 | +26.19% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $133.67 | +12.22% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $74.63 | +13.90% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $77.15 | +16.66% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $19.29 | +65.89% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $30.50 | +47.54% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $20.13 | +123.55% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $390.40 | -19.31% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $309.83 | -4.79% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $10.47 | +52.82% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $19.11 | +72.68% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $91.74 | +74.41% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $534.19 | -41.03% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $2.59 | +208.88% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $9.28 | +169.40% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.07 | +504.12% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $85.04 | +46.99% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $86.18 | +68.25% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $104.58 | -51.23% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $52.34 | +234.35% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $12.21 | +342.26% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $80.74 | -72.75% | 1 | Jul 17, 2017 |
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $169.97
Upside: +53.56%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $253.58
Upside: +26.19%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $133.67
Upside: +12.22%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $74.63
Upside: +13.90%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $77.15
Upside: +16.66%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $19.29
Upside: +65.89%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $30.50
Upside: +47.54%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $20.13
Upside: +123.55%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $390.40
Upside: -19.31%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $309.83
Upside: -4.79%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $10.47
Upside: +52.82%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $19.11
Upside: +72.68%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $91.74
Upside: +74.41%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $534.19
Upside: -41.03%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $2.59
Upside: +208.88%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $9.28
Upside: +169.40%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.07
Upside: +504.12%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $85.04
Upside: +46.99%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $86.18
Upside: +68.25%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $104.58
Upside: -51.23%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $52.34
Upside: +234.35%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $12.21
Upside: +342.26%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $80.74
Upside: -72.75%